Sinalização PI3K/Akt/mTOR
Os inibidores da sinalização PI3K/Akt/mTOR são compostos que têm como alvo as vias da fosfoinositídeo 3-quinase (PI3K), da quinase Akt e do alvo da rapamicina em mamíferos (mTOR). Essas vias são reguladores críticos do crescimento celular, sobrevivência, metabolismo e autofagia, tornando-os alvos-chave na pesquisa de câncer e distúrbios metabólicos. A inibição dessas vias pode ajudar a controlar o crescimento e a proliferação tumoral, oferecendo estratégias terapêuticas potenciais para vários tipos de câncer e outras doenças caracterizadas por sinalização celular desregulada. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de alta qualidade de PI3K/Akt/mTOR para apoiar sua pesquisa em oncologia, sinalização celular e doenças metabólicas.
Subcategorias de "Sinalização PI3K/Akt/mTOR"
- AMPK(159 produtos)
- ATM/ATR(71 produtos)
- DNA-PK(51 produtos)
- EGFR(572 produtos)
- MELK(7 produtos)
- PDK(9 produtos)
- PI3K(242 produtos)
- S6 Quinase(9 produtos)
- gsk-3(112 produtos)
- mTOR(144 produtos)
Exibir 2 mais subcategorias
Foram encontrados 1037 produtos de "Sinalização PI3K/Akt/mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Fórmula:C27H31ClN7O3PCor e Forma:SolidPeso molecular:568.01Lys(CO-C3-p-I-Ph)-O-tBu
CAS:<p>Lys(CO-C3-p-I-Ph)-O-tBu, a pharmacokinetic modifier (PK modifier), enhances the pharmacokinetic properties of PSMA ligand molecules by increasing their residence time in plasma through improved binding to albumin and reducing absorption by the salivary glands, potentially extending the active compound's half-life. Moreover, Ac-PSMA-trillium is an effective PSMA-targeting compound for various biological applications when modified with different radioactive isotopes. When labeled with 111 In, it serves as a DOTA chelating agent and imaging agent. Alternatively, when labeled with 225 Ac, it acts as a Macropa chelator for targeted radionuclide therapy (TRT) in researching metastatic castration-resistant prostate cancer (mCRPC) [1] [2].</p>Fórmula:C20H31IN2O3Cor e Forma:SolidPeso molecular:474.38GSK-3β inhibitor 20
CAS:<p>GSK-3β inhibitor20 (compound 3A) is an effective inhibitor of GSK-3β, exhibiting an IC50 value of 74.4 nM.</p>Fórmula:C22H21N5O2SCor e Forma:SolidPeso molecular:419.50EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Cor e Forma:SolidEGFR-IN-18
<p>EGFR-IN-18 strongly inhibits L858R/T790M/C797S mutant EGFR (4.9 nM) and also targets wild-type EGFR (47 nM).</p>Fórmula:C33H28N6O3SCor e Forma:SolidPeso molecular:588.68EGFR/HER2-IN-7
<p>EGFR/HER2-IN-7: Potent, selective dual inhibitor for MCF-7 cancer; IC50: EGFR 0.18μM, HER2 0.146μM, DHFR 0.907μM.</p>Fórmula:C19H21N3O2SCor e Forma:SolidPeso molecular:355.45SIK2/3-IN-1
CAS:<p>SIK2/3-IN-1 (Compound 7S) is an orally active and selective inhibitor of SIK2/3. It significantly inhibits tumor growth without causing weight loss in the MV4-11 AML mouse CDX model. SIK2/3-IN-1 is applicable for research in MEF2C-dependent acute myeloid leukemia.</p>Fórmula:C20H19F3N6O2Cor e Forma:SolidPeso molecular:432.399PIKfyve-IN-1
<p>PIKfyve-IN-1: potent, cell-active inhibitor for PIKfyve research, IC50=6.9 nM.</p>Fórmula:C20H21N5Cor e Forma:SolidPeso molecular:331.41EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Fórmula:C21H23N3O5Cor e Forma:SolidPeso molecular:397.424GSK3-IN-9
CAS:<p>GSK3-IN-9 (0713) is a selective inhibitor of glycogen synthase kinase 3 (GSK3). It holds potential for research into fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood epilepsy, intellectual disabilities, diabetes, acute myeloid leukemia (AML), autism, and mental disorders.</p>Fórmula:C18H20N4OCor e Forma:SolidPeso molecular:308.378JBJ-09-063
CAS:<p>JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.</p>Fórmula:C31H29FN4O3SCor e Forma:SolidPeso molecular:556.65LSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Fórmula:C21H20ClN3O4Cor e Forma:SolidPeso molecular:413.854PI3Kδ-IN-23
CAS:<p>PI3Kδ-IN-23 (compound A11) is a potent inhibitor of PI3Kδ, with an IC50 of 0.27 nM. It binds to PI3Kδ through covalent interaction with Lys779 and plays a significant role in cancer research.</p>Fórmula:C30H30N6O5Cor e Forma:SolidPeso molecular:554.596Sacibertinib
CAS:<p>Sacibertinib inhibits Trk, targeting EGFR-TK (EC50 110 nM) & HER2 (EC50 244 nM), with anticancer properties.</p>Fórmula:C32H31ClN6O4Cor e Forma:SolidPeso molecular:599.08SST0116CL1
CAS:<p>SST0116CL1 is an HSP90 inhibitor (IC50: 0.21 μM) that targets the ATP-binding pocket of Hsp90, disrupting its chaperone function and leading to the degradation of client proteins (EGFR, CDK4, and AKT). It induces the degradation of Her2 in BT-474 cells (IC50: 0.2 μM) and exhibits antiproliferative activity, inhibiting tumor growth.</p>Fórmula:C22H31ClN4O6Cor e Forma:SolidPeso molecular:482.96PI3kδ inhibitor 1
CAS:<p>PI3kδ inhibitor 1 is a selective inhibitor of PI3Kδ (IC50 of 3.8 nM).</p>Fórmula:C28H33FN6O2Pureza:98%Cor e Forma:SolidPeso molecular:504.60ETP-47037
CAS:<p>ETP-47037: strong PI3Kα inhibitor (IC50: 0.99 nM), also targets PI3Kβ, δ, γ; may protect telomeres.</p>Fórmula:C20H27N9O3SCor e Forma:SolidPeso molecular:473.55AZD 3147
CAS:<p>AZD 3147 inhibits mTORC1 (40.7 nM), mTORC2 (5.75 nM), and PI3Kα/β/δ/γ (912/5495/9333/6310 nM IC50s).</p>Fórmula:C24H31N5O4S2Pureza:99.99%Cor e Forma:SolidPeso molecular:517.66Aldometanib
CAS:<p>Aldometanib (LXY-05-029) is an oral aldolase inhibitor that maintains metabolic balance by blocking FBP and activating lysosomal AMPK.</p>Fórmula:C27H43Cl2IN2Pureza:99.32% - 99.55%Cor e Forma:SolidPeso molecular:593.46BAY-8400
<p>BAY-8400 is an orally active, potent and selective DNA-dependent protein kinase ( DNA-PK ) inhibitor ( IC 50 =81 nM) which shows synergistic efficacy in</p>Fórmula:C21H17F2N5OPureza:99.53%Cor e Forma:SolidPeso molecular:393.39EGFR-IN-7
CAS:<p>EGFR-IN-7 (TQB3804) is a selective and potent EGFR kinase inhibitor.</p>Fórmula:C32H41BrN9O2PPureza:95.32% - 99.64%Cor e Forma:SolidPeso molecular:694.6AS-604850
<p>AS-604850: PI3Kγ inhibitor, ATP-competitive, IC50=2.5μM, 30x> PI3Kδ/β, 18x> PI3Kα.</p>Fórmula:C11H5F2NO4SPureza:98%Cor e Forma:SolidPeso molecular:285.22TLC9995-0188
CAS:<p>Tyrosine-protein kinase ABL, IC50: 1500 nM</p>Fórmula:C16H15N5Cor e Forma:Yellow SolidPeso molecular:277.331Nimotuzumab (powder)
CAS:<p>Nimotuzumab (powder) is a humanized IgG1 monoclonal antibody that specifically targets the epidermal growth factor receptor (EGFR), possessing a dissociation constant (KD) of 0.21 nM. It blocks the binding to its ligand by targeting the extracellular domain of EGFR. Nimotuzumab exhibits strong antitumor activity by inducing both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), exerting cytolytic effects on target tumors.</p>Cor e Forma:LiquidHMBD-001
<p>HMBD-001 is a humanized IgG1 monoclonal antibody inhibitor that targets HER3. By inhibiting the dimerization of HER3, HMBD-001 suppresses the growth and proliferation of tumor cells. It holds potential for research in cancer treatments, specifically for pancreatic cancer and non-small cell lung cancer.</p>Cor e Forma:Odour LiquidAZD8154
CAS:<p>AZD8154 is a newly developed inhaled compound that selectively inhibits dual PI3Kγδ, aimed at treating airway inflammatory diseases.</p>Fórmula:C27H29N5O4S2Cor e Forma:SolidPeso molecular:551.68mTORC1-IN-1
<p>mTORC1-IN-1 (T1), a rapamycin homologue (rapalog) and selective inhibitor of mTORC1, controls cell growth and metabolism, with implications in various diseases</p>Pureza:98%Cor e Forma:Odour SolidSonolisib
CAS:<p>Sonolisib is an irreversible and pan-isoform inhibitor of PI3K (IC50=0.1 nM (p110α), 1.0 nM (p120γ), 2.9 nM (p110δ)).</p>Fórmula:C29H35NO8Pureza:98%Cor e Forma:SolidPeso molecular:525.59Duligotuzumab
CAS:<p>Duligotuzumab (MEHD-7945A) is a bispecific humanised IgG-κ monoclonal antibody targeting HER3 and EGFR, solid tumours, head and neck cancer,colorectal cancer.</p>Pureza:95%Cor e Forma:LiquidRef: TM-T80604
Produto descontinuadoBisindolylmaleimide I HCl
CAS:<p>Bisindolylmaleimide I HCl is a specific ATP-competitive PKC inhibitor.</p>Fórmula:C25H25ClN4O2Pureza:98%Cor e Forma:SolidPeso molecular:448.95EGFR-IN-82
CAS:<p>EGFR-IN-82 (Compound 8a) is a potent, orally active inhibitor of EGFR, exhibiting IC50 values of 0.09 nM for EGFR L858R/T790M/C797S and 0.06 nM for EGFR Del19/</p>Fórmula:C32H41BrN9O2PPureza:98%Cor e Forma:SolidPeso molecular:694.6Ref: TM-T78788
Produto descontinuadoPI3Kδ-IN-13
CAS:<p>PI3Kδ-IN-13 (compound 89), with an IC50 value of 2.6 nM, is an inhibitor of PI3Kδ, applicable for researching diseases involving cell proliferation, including</p>Fórmula:C27H39N7O4S2Cor e Forma:SolidPeso molecular:589.77Duvelisib (R enantiomer)
CAS:<p>Duvelisib R enantiomer (IPI-145 R enantiomer) is an enantiomer of Duvelisib with lower activity. Duvelisib is a PI3K inhibitor.</p>Fórmula:C22H17ClN6OPureza:98%Cor e Forma:SolidPeso molecular:416.86YK-029A
CAS:<p>YK-029A, an orally active EGFR mutant inhibitor, targets both EGFR T790M and EGFRex20ins mutations.</p>Fórmula:C27H32N8O2Pureza:98%Cor e Forma:SolidPeso molecular:500.6Ref: TM-T79461
Produto descontinuadoMDVN1003
CAS:<p>MDVN1003 inhibits BTK & PI3Kδ in B cells, blocking NHL growth; it kills lymphoma cells, not erythroblasts.</p>Fórmula:C22H20FN7OPureza:98%Cor e Forma:SolidPeso molecular:417.44EGFR-IN-123
CAS:<p>EGFR-IN-123 (compound D06) is an effective EGFR inhibitor. It exhibits inhibitory activity against several cell lines including PC-9G, A549, A431, and HCT116, with IC50 values of 0.74, 1.36, 1.20, and 2.53 μM respectively.</p>Fórmula:C24H27F3N6OCor e Forma:SolidPeso molecular:472.51Ref: TM-T200485
Produto descontinuadoEGFR-IN-122
CAS:<p>EGFR-IN-122 (compound Yfq07) serves as a potent inhibitor of EGFR. It effectively inhibits the proliferation of PC-9GR and HCC827GR cells.</p>Fórmula:C19H20N4O3Cor e Forma:SolidPeso molecular:352.39Ref: TM-T200157
Produto descontinuado
